Triple Agonist Peptides: How GLP-1/GIP/Glucagon Drugs Work

Key Takeaways

• What triple agonism is: Simultaneous activation of three hormone receptors — GLP-1R, GIPR, and GCGR — by a single molecule, combining the satiety and insulin effects of GLP-1/GIP with the energy expenditure and hepatic fat effects of glucagon signaling.
• Lead candidate: Retatrutide is the most clinically advanced triple GLP-1/GIP/glucagon agonist as of April 2026; it is investigational and not FDA-approved.
• Phase 2 efficacy: The Jastreboff 2023 NEJM Phase 2 trial (N=338) reported approximately 24% mean body weight reduction at 48 weeks at the 24-mg dose — among the largest mean weight reductions reported in a Phase 2 trial in this drug class at the time of publication.
• Regulatory status: As of April 2026, retatrutide is in Phase 3 trials (TRIUMPH program); an FDA submission is anticipated in late 2026 or 2027. Not lawfully available through compounding.
• Mechanistic distinction from dual agonists: The glucagon receptor arm is proposed to add energy expenditure and hepatic fat oxidation — effects not observed with GLP-1 monotherapy or GIP/GLP-1 dual agonism in published trials — which is the proposed explanation for the larger weight-loss signal seen for retatrutide versus tirzepatide in indirect network meta-analyses (no head-to-head randomized trial completed).
• Evidence gap: No completed head-to-head randomized trial comparing retatrutide to tirzepatide or semaglutide has been published as of April 2026.

From One Receptor to Three: How Triple Agonism Developed

The progression from GLP-1 monotherapy to triple agonism is a deliberate mechanistic strategy grounded in incretin biology. Jakubowska and le Roux traced this development in their 2024 review in Endocrinology and Metabolism (Seoul), describing the road toward triple agonists from incretin discovery to GLP-1/GIP/glucagon triagonism as a logical extension of adding complementary metabolic pathways. GLP-1 was identified as an insulinotropic gut hormone in the 1980s and became the mechanistic foundation for semaglutide and liraglutide. Adding GIP receptor activation — as tirzepatide did — exploited a second incretin with distinct but overlapping benefits. Adding glucagon receptor activation recruited a third mechanism: the energy expenditure and hepatic effects of glucagon, counterbalanced by the GLP-1 arm's insulin-stimulating properties to prevent the hyperglycemia that glucagon receptor stimulation would otherwise produce.

Alfaris and Waldrop described this mechanistic spectrum comprehensively in their 2024 narrative review in eClinicalMedicine, placing GLP-1 single, dual, and triple receptor agonists on a continuum in which each added receptor target contributes a distinct metabolic action to the overall pharmacological effect. This article covers each of the three arms in turn, then explains how the combined profile produces the clinical results observed in retatrutide trials.

The Three Receptors and What Activating Each One Does

GLP-1 receptor: the satiety and insulin foundation

The glucagon-like peptide-1 receptor (GLP-1R) is expressed in the pancreas, small intestine, brain, heart, kidney, and lung. Its activation in the pancreas stimulates glucose-dependent insulin secretion — meaning insulin is released only when blood glucose is elevated, which is why GLP-1 receptor agonists do not cause hypoglycemia at normal glucose levels. In the gut, GLP-1R activation slows gastric emptying, reducing the rate at which glucose enters the bloodstream. In the brain, GLP-1R activation suppresses appetite through central circuits. Kim and colleagues demonstrated in a 2024 Science paper that GLP-1 increases preingestive satiation via dorsomedial hypothalamus GLP-1R neurons in both mice and humans, establishing the central satiety mechanism that all GLP-1 class drugs share. Buller and Blouet reviewed in 2024 in the American Journal of Physiology — Endocrinology and Metabolism how incretins and incretin receptor agonists access brain circuits that regulate food intake, providing the neural anatomy underlying GLP-1's central effects. The established clinical evidence for GLP-1 receptor agonism in obesity is robust: the SELECT trial, published in the New England Journal of Medicine in 2023 by Lincoff and colleagues, demonstrated that semaglutide reduces major adverse cardiovascular events by 20% over 33 months in obese non-diabetic adults — establishing GLP-1 receptor agonism as a class with demonstrated cardiovascular benefit in this population alongside its metabolic effects.

GIP receptor: the amplifier

The glucose-dependent insulinotropic polypeptide receptor (GIPR) was historically viewed primarily as a pancreatic receptor driving insulin secretion in response to meals — the classic "incretin effect" shared with GLP-1. The rationale for adding GIP receptor agonism to GLP-1R activation was initially counterintuitive: GIP receptor agonism in isolation was known to produce modest weight effects, yet tirzepatide's Phase 3 trials showed that dual GIP/GLP-1 agonism substantially outperformed GLP-1 monotherapy for weight loss. Nauck and D'Alessio explored this paradox in their foundational 2022 review in Cardiovascular Diabetology, establishing that dual GIP/GLP-1 agonism produces greater weight loss than GLP-1 monotherapy through mechanisms that include central GIPR signaling and possibly reduced GLP-1-associated nausea. A meta-analysis of tirzepatide randomized controlled trials by Mesquita and colleagues, published in the International Journal of Obesity in 2023, pooled efficacy and adverse-event data across tirzepatide trials, confirming the superiority over GLP-1 monotherapy that justified adding GIP as a third target when designing triple agonists. Bailey and Flatt's 2025 comprehensive review in Peptides covered the multifunctional incretin peptide mechanisms of GLP-1 and GIP together, providing the mechanistic reference for how both incretin arms contribute to the combined pharmacological profile.

Glucagon receptor: the energy expenditure arm

The glucagon receptor (GCGR) is the most pharmacologically novel addition to the triple agonist architecture. Glucagon is secreted by pancreatic alpha cells and classically opposes insulin's effects: it mobilizes glucose from liver glycogen stores and promotes hepatic gluconeogenesis. In isolation, GCGR agonism would produce hyperglycemia — a clear liability for a metabolic drug. The triple agonist strategy resolves this by co-activating GLP-1R simultaneously: the insulin-stimulating effect of GLP-1R activation neutralizes the hyperglycemic potential of glucagon receptor agonism. What remains from GCGR activation, unmasked by the GLP-1 counterbalance, is a thermogenic and lipolytic effect that neither GLP-1R nor GIPR can produce alone. Winther and Holst reviewed the glucagon receptor's metabolic contribution in a 2024 paper in Diabetes, Obesity and Metabolism, documenting that glucagon receptor agonism increases energy expenditure, enhances lipolysis, and reduces hepatic fat. Corbin and colleagues provided direct Phase 2 human evidence in a 2023 Obesity trial, demonstrating that GLP-1/glucagon receptor agonism reduces metabolic adaptation and increases fat oxidation — the thermogenic mechanism that the triple agonist glucagon arm is proposed to amplify. Targher and colleagues reviewed in Gut in 2025 how GLP-1 receptor agonists have demonstrated hepatoprotective signals across MASLD trials through mechanisms that the glucagon component in triple agonists is proposed to amplify further through direct hepatic fat oxidation pathways.

How Triple Agonism Works in Practice: Retatrutide's Investigational Clinical Evidence

Retatrutide is the most clinically advanced triple GLP-1/GIP/glucagon agonist in human trials. As of April 2026, it has completed Phase 2 trials and advanced to Phase 3 (TRIUMPH program), with topline Phase 3 data reported but not yet peer-reviewed in a journal.

Phase 2 obesity trial: NEJM 2023 results

The primary efficacy anchor for retatrutide is the Phase 2 randomized controlled trial published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues (N=338, 48 weeks, adults with obesity without type 2 diabetes). Participants at the 24-mg dose achieved a mean body weight reduction of approximately 24% compared to 2.1% with placebo. Dose-dependent weight loss was observed across the evaluated dose range; lower doses produced proportionally lower weight reductions. No head-to-head randomized trial has compared retatrutide to tirzepatide or semaglutide. For cross-trial contextual reference only — across different trial phases, populations, and durations — tirzepatide at its highest approved dose reported approximately 21% mean body weight reduction in the SURMOUNT-1 Phase 3 trial and semaglutide 2.4 mg reported approximately 15% in the STEP 1 Phase 3 trial, compared to retatrutide's approximately 24% at 24 mg in the Jastreboff 2023 NEJM Phase 2 trial. These comparisons are indirect and are not a substitute for a head-to-head randomized trial. Phase 3 topline data from the TRIUMPH program reported approximately 29% mean body weight reduction at 68 weeks in company disclosures; these data have not yet been published in a peer-reviewed journal as of April 2026.

Phase 2 type 2 diabetes trial: Lancet 2023 results

The Phase 2 RCT in adults with type 2 diabetes, published in The Lancet in 2023 by Rosenstock and colleagues, demonstrated significant HbA1c and body weight reductions versus placebo and an active comparator. This trial established that the triple agonist mechanism produces meaningful glycemic improvement alongside weight loss in the T2D population — consistent with the GLP-1 arm's glucose-dependent insulin-stimulating action — and that the glucagon arm does not produce net hyperglycemia when co-administered with a GLP-1 agonist.

MASLD Phase 2a trial: Nature Medicine 2024 results

The proposed hepatic benefit of the glucagon arm found clinical support in a Phase 2a trial in metabolic dysfunction-associated steatotic liver disease, published in Nature Medicine in 2024 by Sanyal and colleagues. In this Phase 2a investigational trial, retatrutide was associated with clinically meaningful liver fat reduction and improved insulin sensitivity in participants with MASLD. These findings are consistent with the proposed GCGR-mediated hepatic fat oxidation mechanism described by Winther and Holst. Phase 3 liver outcomes data are pending; retatrutide is not approved for MASLD or any indication.

Network meta-analysis comparison (Sinha and Ghosal, Obesity 2025)

A Bayesian network meta-analysis published in Obesity in 2025 by Sinha and Ghosal used indirect comparison methodology to evaluate GLP-1 receptor agonists, dual agonists, and retatrutide across randomized controlled trials. The analysis ranked retatrutide highest in indirect comparison within the network. A network meta-analysis is more statistically rigorous than simple cross-trial comparison, but it is not equivalent to a head-to-head randomized trial. The result indicates that retatrutide's efficacy signal is consistent with superior weight loss in indirect comparisons; it does not establish superiority in a direct head-to-head study, which has not yet been completed.

Triple Agonism Versus Dual Agonism: What the Evidence Actually Supports

The mechanistic argument for triple agonism over dual agonism rests on the glucagon arm producing effects — increased energy expenditure, reduced hepatic fat — that the GIP and GLP-1 arms do not. The clinical evidence is consistent with this argument: retatrutide's Phase 2 weight-loss numbers are numerically larger than tirzepatide's published Phase 3 numbers, though cross-trial comparison across different phases, populations, and durations is not a substitute for a head-to-head trial. However, the following caveats apply:

• The phase 2 data for retatrutide (Jastreboff 2023) and the Phase 3 data for tirzepatide (SURMOUNT-1) come from different trials with different populations, designs, and time points. No head-to-head randomized trial has directly compared them.
• Retatrutide's Phase 3 data are topline only; peer-reviewed publication is pending.
• The approximately 24% Phase 2 weight loss for retatrutide used a 24-mg dose; the comparator data for tirzepatide used its approved 15-mg maximum dose. Dose comparability is not established.
• Increased heart rate documented in retatrutide's Phase 2 (attributed to the glucagon arm) is a potential liability not present in dual agonists; its cardiovascular significance requires Phase 3 outcome data.

Kaur and Misra reviewed retatrutide's pharmacology and outstanding Phase 3 data gaps in a 2024 paper in the European Journal of Clinical Pharmacology, noting that phase 3 data are required before definitive conclusions about the triple agonist's advantages over existing approved compounds can be drawn. Goldney and Hamza's 2025 review in Current Cardiovascular Risk Reports examined triple-agonism-based therapies for cardiometabolic risk factor improvements, noting the cardiovascular rationale for targeting all three receptors but acknowledging the need for completed Phase 3 cardiovascular outcome trials.

Side Effects and Safety Considerations

The safety profile of triple agonists in human trials reflects the GLP-1 class adverse event burden with a compound-specific addition from the glucagon arm.

GLP-1 class gastrointestinal effects

Nausea, vomiting, diarrhea, and constipation are the most common adverse events across all GLP-1 class drugs, including retatrutide. A 2025 systematic review in the Annals of Internal Medicine by Moiz and colleagues documented gastrointestinal adverse events as the dominant safety concern across GLP-1 agonists and co-agonists in non-diabetic adults. In the retatrutide Phase 2 trial, GI adverse events were dose-dependent and predominantly occurred during the dose-escalation period. Discontinuation due to adverse events was approximately 16% at the 24-mg dose in the Jastreboff 2023 Phase 2 obesity trial.

Glucagon arm: heart rate and glycemic considerations

The glucagon receptor arm in retatrutide introduces compound-specific adverse event considerations not shared by GLP-1 monotherapy or dual agonists. Increased resting heart rate — approximately 3 to 5 beats per minute in Phase 2 data — was documented in participants receiving retatrutide. This is attributed to glucagon receptor activation in the heart and adrenergic pathways. The long-term cardiovascular significance of this heart rate increase is not established; Phase 3 trials include cardiovascular outcome endpoints. The glycemic balance of the triple agonist's GLP-1 and glucagon arms was maintained in Phase 2 trials, with HbA1c improving rather than worsening — consistent with the GLP-1 component's dominant glycemic effect.

Beyond weight loss: liver and cardiometabolic effects

Triple agonism's proposed benefits extend beyond the appetite suppression that is the primary mechanism of GLP-1 monotherapy. The hepatic fat reduction seen in retatrutide's MASLD Phase 2a trial suggests a distinct clinical application for MASLD, a condition affecting a substantial proportion of adults with obesity for whom GLP-1 monotherapy provides benefit primarily through weight loss. The glucagon arm's hepatic mechanism is distinct from GLP-1's: it promotes active fat oxidation within the liver rather than reducing fat delivery through weight loss alone. Lempesis and Dalamaga, in their 2026 review in Metabolism Open, described the broader implications of multi-receptor agonists for next-generation metabolic modulation — areas that require dedicated Phase 3 investigation but illustrate the range of proposed mechanisms under active investigation for the triple-agonist class.

Wilbon and Kolonin reviewed in Cells in 2023 how GLP-1 receptor agonist effects extend beyond obesity and diabetes to cardiovascular, neurodegenerative, and renal implications — the preclinical and early clinical signals that position the triple agonist class as a potentially broad-acting metabolic intervention across multiple pathways.

Regulatory Status and Availability

As of April 2026, retatrutide — the lead triple GLP-1/GIP/glucagon agonist — is in Phase 3 trials (TRIUMPH program) and is not FDA-approved for any indication. An FDA submission is anticipated in late 2026 or 2027; approval, if granted, is not expected before 2028. Because retatrutide is not FDA-approved, does not appear on the FDA's 503A bulk drug substances list, and is not a component of any approved drug, it is not lawfully available through compounding pharmacies in the United States. Kokkorakis and colleagues' 2025 systematic review in Pharmacological Reviews positioned retatrutide among the emerging obesity pharmacotherapies in the incretin pipeline, situating the triple agonist class within the broader landscape of next-generation candidates approaching regulatory review.

What to Test Before the Triple Agonist Class Becomes Available

The transition from currently approved dual agonists to a triple agonist class — when it occurs — will be most meaningful for patients with an established metabolic baseline. The glucagon arm's hepatic and thermogenic effects make liver function and metabolic markers particularly relevant beyond the standard GLP-1 pre-treatment panel.

• Fasting glucose: Baseline glycemic status is foundational before any drug affecting insulin and glucagon signaling. A fasting glucose measurement establishes where you start and makes subsequent changes interpretable.
• HbA1c: The 2 to 3 month average of blood glucose that distinguishes non-diabetic obesity from pre-diabetes and T2D. HbA1c is the primary glycemic endpoint in trials of both dual and triple agonists.
• Fasting insulin: Characterizes insulin resistance before treatment. Fasting insulin changes during GLP-1 class therapy reflect improving metabolic function.
• Liver enzymes (ALT, AST): Because the glucagon arm in triple agonists targets hepatic fat oxidation, baseline liver enzymes are more than a standard pre-treatment check — they establish the liver's starting point for a compound whose Phase 2a MASLD data showed substantial fat reduction. Reviewing liver health biomarkers provides context for interpreting these values.
• Triglycerides: Reflect hepatic fat metabolism and are sensitive to the kind of metabolic changes triple agonists are proposed to produce. A baseline triglyceride measurement is part of the standard metabolic panel for this drug class.
• eGFR and creatinine: Renal function establishes eligibility and affects pharmacokinetics for compounds in this class. A baseline eGFR is standard clinical practice.
• TSH: Approved GLP-1 receptor agonists carry a Boxed Warning for thyroid C-cell tumor risk and a contraindication in personal or family history of MTC / MEN 2. Baseline TSH is standard clinical practice before initiating this class.
• IGF-1: The glucagon receptor arm's influence on hepatic signaling pathways has downstream effects on growth hormone-related metabolism. Reviewing IGF-1 levels provides baseline context for these pathways, though IGF-1 is not a primary monitoring marker for GLP-1 class drugs.

Understanding Your Baseline

Triple agonist peptides represent the current frontier of incretin pharmacology — a mechanistic extension of the GLP-1 class that adds hepatic and thermogenic effects to the satiety and insulin benefits established over two decades of GLP-1 drug development. That the frontier is investigational as of April 2026 does not diminish its relevance. Understanding the mechanism, knowing the evidence quality, and establishing a metabolic baseline now means the clinical conversation is more productive when these compounds become prescribable.

That principle is foundational to Superpower's approach to preventive health: objective data precedes every clinical decision. When a triple agonist reaches your clinical conversation, the relevant question will not be "what does the headline percentage mean?" It will be: "what does my metabolic baseline say about whether this drug's specific mechanism is relevant to my biology?" That question requires data.

IMPORTANT SAFETY INFORMATION: Retatrutide

Retatrutide is an investigational drug currently under clinical development by Eli Lilly and Company (TRIUMPH program). It has not been approved by the FDA, or any other regulatory authority, for any medical use as of April 2026. Because retatrutide is not FDA-approved, does not appear on the FDA's 503A bulk drug substances list, and is not a component of any approved drug, it is not lawfully available through compounding pharmacies in the United States. Retatrutide is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.

Phase 3 safety data from the TRIUMPH program are not yet fully published as of April 2026. Phase 2 safety data documented nausea, vomiting, diarrhea, constipation, and increased resting heart rate (approximately 3 to 5 bpm) as the most common adverse events. Discontinuation due to adverse events was approximately 16% at the 24-mg dose in Phase 2. Long-term cardiovascular safety, including the significance of the documented heart rate increase, has not been established. Weight regain following discontinuation of GLP-1 class drugs has been documented in clinical trials.

The following populations were not enrolled in Phase 2 trials or have not been specifically studied: pregnancy and breastfeeding; severe renal or hepatic impairment. Approved GLP-1 receptor agonists (e.g., semaglutide, tirzepatide, liraglutide) carry a Boxed Warning for thyroid C-cell tumor risk based on rodent data and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Retatrutide's labeling, if approved, would be subject to the same class-level FDA thyroid safety review. The clinical significance of the rodent C-cell signal in humans continues to be evaluated. Always consult a licensed healthcare provider before making any clinical decisions related to this compound class.

Superpower does not prescribe, sell, compound, or facilitate access to retatrutide. See the Important Safety Information above for full investigational-status language.